PROTOCOL: SHP620-303 A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infection

Project: Research project

Project Details

StatusActive
Effective start/end date3/24/173/24/21

Funding

  • PPD Development (SHP620-303)
  • Shire ViroPharma Incorporated (SHP620-303)